@OncLive

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

 New Jersey, USA
onclive.com
Joined May 2009
  • Tweets121K
  • Following2K
  • Followers50.5K
24.5KMedia
It's somehow time for our last day of ✨LIVE✨ filmings at this year's @myESMO #ESMO26 Congress! 🎥 Are you in Madrid and presenting key data? Reach out to our team to set up an exclusive interview. We would love to speak with you! Follow along for the latest updates from the meeting and to see who we have in the chair today 👉: onclive.com/conference/esmo-…
1
3
5
513
Host @CParkMD sits down with Alexandra Drakaki, MD, PhD, and @sonpavde, for a real-time read on perioperative EV, ctDNA-guided adjuvant therapy, and what’s next in muscle-invasive bladder cancer at the 2026 ESMO Congress! 🌎 Tune in today: hubs.li/Q04CtQ6Q0 #blcsm #ESMO26
1
2
148
With bispecifics, ADCs, and CAR T all targeting BCMA, sequencing in relapsed/refractory myeloma is the real question. Hans Lee, MD, Jing Christine Ye, MD, MSc, Douglas W. Sborov, MD, MS, and Paul G. Richardson, MD weigh in. Watch now on OncLive®: hubs.li/Q04zbm6p0 @SarahCannonDocs @UTMDAnderson @huntsmancancer @DanaFarber #mmsm #BCMA #Bispecifics
1
2
245
Is docetaxel still the bar after immunotherapy in squamous NSCLC? Jacob Sands, MD, Narjust Florez, MD, Christian Rolfo, MD, PhD, and Edward S. Kim, MD, MBA weigh where ADCs and bispecifics fit in second line. Watch the OncLive® Peer Exchange: hubs.li/Q04zbhK60 @sands_jacob @NarjustFlorezMD @DanaFarber @ChristianRolfo @OSUCCC_James @DrEdKim @cityofhope #lcsm #NSCLC #ADCs
226
📰Just in: T-cell–redirecting therapies continue to demonstrate improvements in early-relapse myeloma. Topline data from the phase 3 MagnetisMM-32 trial showed elranatamab improved PFS vs SOC in R/R multiple myeloma treated with at least 1 prior line of therapy that included an anti-CD38 monoclonal antibody and lenalidomide #mmsm #oncology onclive.com/view/elranatamab…
5
4
339
📰 The European Commission has approved T-DXd monotherapy for patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment with a taxane and HER2-directed therapy. #bcsm #oncology Read more ➡️: onclive.com/view/t-dxd-gains…
1
2
309
Oncology fellows: share your genitourinary cancer research with peers and leading GU faculty at the OncLive® National Fellows Forum, Feb 10, 2027, in San Francisco. Abstracts due Dec 31. Submit your abstract: hubs.li/Q04C9f9W0 #pcsm #blcsm #kcsm
4
368
OncLive.com retweeted
Hope Rugo@hoperugoOct 26
#ESMO26 nice summary by Antonio Llombart on CNS studies in mHER2 positive disease! Congrats to all. @OncoAlert
19
33
1,368
#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors
16
29
1,970
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
DESTINY-Breast09 CNS Analysis Assessment of pts with BICR-assessed brain mets (treated and asymptomatic or clinically inactive) n=61 Deeper systemic and CNS response, and higher iORR @OncoAlert #ESMO26
1
15
23
1,120
Congrats @drchoueiri @danafarber on a very well delivered presentation, encompassing a lot of the data we need to understand the "why" (i.e., toxicity burden, discontinuation, etc.). I personally think the next phase of 1L drug development with #kidneycancer (if we are to proceed with triplets) will have to involve agents with a wide therapeutic index so administration of Drug 3 does not cause delays/interruptions w Drug 1 + 2. In this regard, hopeful for @SWOG #S2419 (#BIOFRONT) led by @PBarataMD, investigating IO-backbone +/- #MO03 (a live bacterial product). #ESMO26 @oncoalert @brian_rini @tompowles1
Toni Choueiri, MD
@DrChoueiriOct 25
More is not always better in 1L RCC! Presenting LITESPARK-012 Ph.III: adding belzutifan or CTLA-4 blockade to Pembro/Len failed to improve PFS or OS. PFS HR 1.08/1.07; OS HR 1.04/1.12. ORR 69%/69% vs 76% SOC. #ESMO26 #RCC @myESMO @OncoAlert
1
13
34
1,643
More is not always better in 1L RCC! Presenting LITESPARK-012 Ph.III: adding belzutifan or CTLA-4 blockade to Pembro/Len failed to improve PFS or OS. PFS HR 1.08/1.07; OS HR 1.04/1.12. ORR 69%/69% vs 76% SOC. #ESMO26 #RCC @myESMO @OncoAlert
2
28
1
64
4,365
Exciting data at #ESMO26 by Dr. Liangyou Gu on novel imagining for kidney CA 🩻 💫 novel CAIX-targeted [68Ga] PET provides accurate primary ccRCC identification and superior detection of lymph node, lung & bone mets over regular 2-[18F]FDG PET, esp in small-volume lesions
1
11
21
1,002
OncLive.com retweeted
Tom Powles
@tompowles1Oct 26
The MOIO randomised phase 3 non-inferiority trial (n=340) explored early discontinuation of ICI therapy be SOC in advanced patients responding to therapy. It had many flaws (mixed tumors and treatments, small size, early discontinuation etc). Also, due to the statistics, it’s not possible to say whether non-inferiority was achieved (OS HR 1.89 [95%Cl: 1.03,3.48]). Despite these problems it highlights a concern around early discontinuation, which should be taken seriously. Tumour specific trials are needed, but I’m not sure it will be easy to randomize patients . #ESMO26 @OncoAlert @myESMO @Annals_Oncology
2
25
41
2,268
Upper GI #RapidOral session at @myESMO #ESMO26 iKRAS G12D PDAC HRS-4642 + chemo + PDL1 🤩Perioperative🤩 ✅ORR - above 60% 🤔R0 - 100% 😊Reports pathological response 💪Good signal, let’s pursue #ESMOAmbassadors
12
2
35
6,290
OncLive.com retweeted
Sara Coca Membribes@scocmemOct 26
A valuable session on mentorship and career development at #ESMO26 @myESMO Thanks to @FerMosele @AndresC27622123 @LoiSher for sharing their insights @OncoAlert
9
22
1,029
Important longer follow up from DeLLphi-304 (2L tarlatamab vs SCLC) presented by Dr. @charlesrudin at #ESMO26 simultaneously published @Annals_Oncology. Median PFS 4.2 vs 3.2m, mOS 13.6 vs 8.4m, 2y OS 30% vs 15%, RR 35% vs 20% #ESMOAmbassadors annalsofoncology.org/article…

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based...

In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and...

annalsofoncology.org
1
13
38
2,196
#ESMO26 Dr. Mary O'Brien presents final analysis of phase III PEARLS/KEYNOTE-091 trial: adjuvant pembrolizumab for resected NSCLC with 87m f/u. In pts who received adjuvant chemo, DFS 58.7 vs 39.1m (HR 0.80) and no difference in survival: OS HR 0.91 with 6y DFS 69% vs 65%. In that group, improved lung cancer specific survival (HR 0.69, 6y rate 82% vs 75%). #ESMOAmbassadors
1
15
26
2,615
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
Beautiful presentation by @PTarantinoMD on paired pre/post biopsies on ADC Multifactorial resistance mechanisms for ADCs @OncoAlert #ESMO26
1
25
48
1,973
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
SWITCH trial: ADC switching 25% HR+ 75% TNBC ORR: 0-8.3%, PFS 1.4-3.0 mo @OncoAlert #ESMO26
25
47
2,243
Beautiful discussion of #MOIO at #ESMO26 - a masterclass in distilling a high impact clinical trial into clinically relevant take home messages! Bravo @DrJNaidoo! @OncoAlert
2
13
1
38
2,368
Load more